Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R‐CHOP14: A SAKK 38/07 trial post‐hoc analysis

2021 ◽  
Author(s):  
Luca Ceriani ◽  
Lisa Milan ◽  
Luciano Cascione ◽  
Giuseppe Gritti ◽  
Federico Dalmasso ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Post Hoc Analysis ◽  
Large B Cell Lymphoma ◽  
Post Hoc ◽  
Large B Cell

scholarly journals Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood ◽  
2020 ◽  
Vol 135 (23) ◽  
pp. 2106-2109 ◽  
Author(s):  
Sattva S. Neelapu ◽  
Caron A. Jacobson ◽  
Olalekan O. Oluwole ◽  
Javier Munoz ◽  
Abhinav Deol ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Complete Response ◽  
Durable Response ◽  
T Cell Therapy ◽  
Large B Cell Lymphoma ◽  
Pivotal Study ◽  
Post Hoc ◽  
Large B Cell

Neelapu and colleagues report a post hoc subgroup analysis from the ZUMA-1 trial of chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B cell lymphoma. In comparison with younger patients, those ≥65 years old have similar rates of complete response and durable response at 2 years, but higher rates of neurological toxicity.

Sign in / Sign up

Export Citation Format

Share Document